Paratek Pharmaceuticals, Inc.
PRTK · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $38,062 | $29,208 | $72,627 | $27,845 |
| % Growth | 30.3% | -59.8% | 160.8% | – |
| Cost of Goods Sold | $4,368 | $6,244 | $10,312 | $4,372 |
| Gross Profit | $33,694 | $22,964 | $62,315 | $23,473 |
| % Margin | 88.5% | 78.6% | 85.8% | 84.3% |
| R&D Expenses | $8,772 | $7,308 | $14,268 | $8,486 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $36,264 | $33,489 | $53,814 | $33,846 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$56 | -$2,028 | -$2,930 | -$2,368 |
| Operating Expenses | $43,105 | $38,769 | $65,152 | $39,964 |
| Operating Income | -$9,411 | -$15,805 | -$2,837 | -$16,491 |
| % Margin | -24.7% | -54.1% | -3.9% | -59.2% |
| Other Income/Exp. Net | -$5,091 | -$4,277 | -$4,263 | -$4,389 |
| Pre-Tax Income | -$14,502 | -$20,082 | -$7,100 | -$20,880 |
| Tax Expense | $51 | $61 | $57 | $4,389 |
| Net Income | -$14,553 | -$20,143 | -$7,157 | -$25,269 |
| % Margin | -38.2% | -69% | -9.9% | -90.7% |
| EPS | -0.25 | -0.35 | -0.13 | -0.46 |
| % Growth | 28.6% | -169.2% | 71.7% | – |
| EPS Diluted | -0.25 | -0.35 | -0.13 | -0.46 |
| Weighted Avg Shares Out | 57,282 | 56,903 | 54,388 | 55,166 |
| Weighted Avg Shares Out Dil | 57,282 | 56,903 | 54,388 | 55,166 |
| Supplemental Information | – | – | – | – |
| Interest Income | $252 | $221 | $327 | $186 |
| Interest Expense | $5,287 | $4,476 | $4,558 | $4,536 |
| Depreciation & Amortization | $46 | $246 | $381 | $276 |
| EBITDA | -$9,169 | -$15,559 | -$2,456 | -$16,215 |
| % Margin | -24.1% | -53.3% | -3.4% | -58.2% |